Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

This study tests whether adding cadonilimab (an immunotherapy drug) to standard chemotherapy plus bevacizumab improves outcomes as a first-line treatment for people with malignant pleural mesothelioma — a rare cancer of the lining of the lungs — that cannot be surgically removed. **You may be eligible if...** - You have confirmed malignant pleural mesothelioma that is not eligible for curative surgery - You have not previously received systemic treatment for advanced disease - You have measurable disease on imaging - Your general health score (ECOG) is 0 or 1 - Your blood counts and organ function are adequate **You may NOT be eligible if...** - Your mesothelioma is in the abdomen, around the heart, or in the testicular lining (not pleural) - You have untreated brain metastases - You have an active autoimmune disease - You have serious uncontrolled medical conditions - You used traditional Chinese herbal medicine or immune-modulating agents recently Talk to your doctor to see if this trial is right for you.